Ironwood Pharma (IRWD) Tops Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
- Shipping stocks on fire — but cracks are forming in the rate rally
Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2015 Investor Update
February 18, 2016 4:05 PM ESTKey advancements within three blockbuster opportunities: IBS-C/CIC, vascular/fibrotic diseases and refractory GERD
LINZESS® (linaclotide) U.S. net sales increased ~53% to $455 million in 2015; on track to exceed $1 billion in net sales by 2020
Ironwood revenue increased >95% to $150 million in 2015, primarily driven by continued growth in LINZESS net sales and expansion in commercial margin to ~46%
Delivered on 2015 financial guidance with strong business execution
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
